research The Spectrum of Cutaneous Adverse Events During Encorafenib and Binimetinib Treatment in B-Rapidly Accelerated Fibrosarcoma-Mutated Advanced Melanoma
The combination of encorafenib and binimetinib caused few skin issues.
Search
forLearn
0 / 0 results — no results
Research
5 / 12 results
research BAYONET Trial: Staged Combination With Encorafenib, Binimetinib, Plus Cetuximab Following Encorafenib Plus Cetuximab for BRAF V600E-Mutant Metastatic Colorectal Cancer
The combination treatment showed a higher response rate but no significant survival benefits.
research Clinical Management of Cutaneous Adverse Events in Patients on Targeted Anticancer Therapies and Immunotherapies: A National Consensus Statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology
Spanish experts provided guidelines for treating skin side effects in cancer patients on new therapies, stressing early action and teamwork.
research New Small Molecules in Dermatology: For Autoimmunity, Inflammation, and Beyond
New small molecule drugs show promise in treating complex skin diseases but need more safety research.
research Cutaneous Toxicities of New Targeted Cancer Therapies: Must Know for Diagnosis, Management, and Patient-Proxy Empowerment
New targeted cancer drugs can cause skin side effects, and managing them requires patient education and timely care.
Community Join
0 / 0 results — no results